Comparative studies of various antiemetic regimens

Area of Science:

• Oncology
• Pharmacology
• Clinical Therapeutics

Background:

• Chemotherapy-induced emesis remains a significant challenge for patients undergoing cancer treatment.
• Metoclopramide was an early treatment, but advancements have led to more effective antiemetic strategies.
• The combination of serotonin receptor 3 (5-HT3) antagonists and dexamethasone is now a standard for preventing chemotherapy-induced emesis.

Purpose of the Study:

• To evaluate the comparative efficacy and tolerability of different serotonin receptor 3 (5-HT3) antagonists in preventing chemotherapy-induced emesis.
• To provide guidance on selecting the most appropriate 5-HT3 antagonist for clinical practice.

Main Methods:

• Review of preclinical data on 5-HT3 receptor antagonist properties (selectivity, potency, dose-response, duration).
• Analysis of twelve previous comparative studies, noting their limitations (sample size, blinding, lack of steroid co-administration).
• Inclusion of three recent, large-scale, double-blind comparative studies in the analysis.

Main Results:

• Preclinical studies indicated potential differences among 5-HT3 antagonists.
• Previous comparative trials had significant methodological shortcomings, preventing definitive conclusions.
• Three recent large, well-conducted double-blind studies demonstrated nearly identical antiemetic efficacy and tolerability for all evaluated 5-HT3 antagonists.

Conclusions:

• The choice between different 5-HT3 receptor antagonists should not be based on efficacy or tolerability, as they are comparable.
• The primary determinant for selecting a 5-HT3 antagonist should be its acquisition cost per dose within a specific country.
• This cost-effectiveness approach optimizes resource allocation in antiemetic therapy.